Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Larney

Showing results (121-130 of 187) with videos related to

Pageof 19
Sort By:
The International Journal on Drug Policy|February 9, 2023
HCV treatment initiation in the era of universal direct acting antiviral coverage - Improvements in access and persistent barriersNathalie Jiang, Julie Bruneau, Iuliia Makarenko, et al.
International Journal of Mental Health and Addiction|July 24, 2025
Binge Drug Injection in a Cohort of People Who Inject Drugs in Montreal: Characterizing the Substances and Social Contexts InvolvedNanor Minoyan, Stine Bordier Høj, Didier Jutras-Aswad, et al.
Drug and Alcohol Review|May 14, 2024
Determinants of psychological distress during the COVID-19 pandemic among people who use drugs in Montreal, CanadaIuliia Makarenko, Nanor Minoyan, Stine Bordier Høj, et al.
JAMA Psychiatry|December 27, 2019
All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids: A Systematic Review and Meta-analysisSarah Larney, Lucy Thi Tran, Janni Leung, et al.
Drug and Alcohol Review|August 19, 2020
Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, AustraliaBanafsheh Moradmand-Badie, Lucy Tran, Noora Oikarainen, et al.
Drug and Alcohol Dependence|June 24, 2026
The impact of severe mental illness on treatment retention and all-cause mortality among people in opioid agonist treatmentNatasa Gisev, Thomas Santo, Julia Lappin, et al.
The International Journal on Drug Policy|November 19, 2021
Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supplyWai Chung Tse, Filip Djordjevic, Viandro Borja, et al.
Addiction (Abingdon, England)|May 12, 2021
The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort studyChrianna Bharat, Sarah Larney, Sebastiano Barbieri, et al.
International Journal of Epidemiology|October 16, 2020
Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, AustraliaSarah Larney, Nicola Jones, David A Fiellin, et al.
Lancet (London, England)|June 2, 2015
Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trialJosiah D Rich, Michelle McKenzie, Sarah Larney, et al.
Pageof 19

Showing results (121-130 of 187) with videos related to

Sort By:
Pageof 19
The International Journal on Drug Policy|February 9, 2023
HCV treatment initiation in the era of universal direct acting antiviral coverage - Improvements in access and persistent barriersNathalie Jiang, Julie Bruneau, Iuliia Makarenko, et al.
International Journal of Mental Health and Addiction|July 24, 2025
Binge Drug Injection in a Cohort of People Who Inject Drugs in Montreal: Characterizing the Substances and Social Contexts InvolvedNanor Minoyan, Stine Bordier Høj, Didier Jutras-Aswad, et al.
Drug and Alcohol Review|May 14, 2024
Determinants of psychological distress during the COVID-19 pandemic among people who use drugs in Montreal, CanadaIuliia Makarenko, Nanor Minoyan, Stine Bordier Høj, et al.
JAMA Psychiatry|December 27, 2019
All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids: A Systematic Review and Meta-analysisSarah Larney, Lucy Thi Tran, Janni Leung, et al.
Drug and Alcohol Review|August 19, 2020
Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, AustraliaBanafsheh Moradmand-Badie, Lucy Tran, Noora Oikarainen, et al.
Drug and Alcohol Dependence|June 24, 2026
The impact of severe mental illness on treatment retention and all-cause mortality among people in opioid agonist treatmentNatasa Gisev, Thomas Santo, Julia Lappin, et al.
The International Journal on Drug Policy|November 19, 2021
Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supplyWai Chung Tse, Filip Djordjevic, Viandro Borja, et al.
Addiction (Abingdon, England)|May 12, 2021
The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort studyChrianna Bharat, Sarah Larney, Sebastiano Barbieri, et al.
International Journal of Epidemiology|October 16, 2020
Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, AustraliaSarah Larney, Nicola Jones, David A Fiellin, et al.
Lancet (London, England)|June 2, 2015
Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trialJosiah D Rich, Michelle McKenzie, Sarah Larney, et al.
Pageof 19